Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Trump Media and Technology Group Corp (DJT) vs Enveric Biosciences Inc (ENVB) Price & Performance

Trump Media and Technology Group CorpTrade
Enveric Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Trump Media and Technology Group Corp vs Enveric Biosciences Inc — how do they compare? Trump Media and Technology Group Corp trades at $9.15 (market cap $2.50B), while Enveric Biosciences Inc trades at $1.33 (market cap $5.32M). The key difference: Trump Media and Technology Group Corp is far larger — about 469.9× Enveric Biosciences Inc's market cap, and Trump Media and Technology Group Corp is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.

DJTENVB
Market Cap
$2.50B$5.32M
Sector
MediaHealth
52-Week High
$19.86$17.40
52-Week Low
$7.06$1.28
Enterprise Value
$2.45B$408.82K

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Trump Media and Technology Group Corp

DJT trades at $8.52, down 0.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported minimal revenue of $3.68M in 2025 alongside a massive net loss of -$712.06M, reflecting severe profitability challenges. Recent news highlights a nearly 50% stock decline in 2026 and the cancellation of a Truth Social spin-off, while a merger with TAE Technologies aims to pivot toward nuclear fusion energy.

The outlook remains highly speculative, with the stock's meme-driven volatility and fundamental weaknesses posing significant risks. Investment opportunity hinges on successful execution of the TAE merger and fusion technology prospects, but persistent losses and high valuation ratios suggest substantial downside potential if growth fails to materialize.

Enveric Biosciences Inc

ENVB trades at $1.33, down 1.48% on the day, with a bearish technical signal from moving averages despite neutral oscillators. The company shows significant financial challenges with negative ROE of -257.95% and ROA of -218.01%, though it has consistently beaten earnings expectations in recent quarters. Recent news highlights active participation in investor conferences and progress with EB-003 drug candidate development.

While analyst consensus is 75% buy-rated, the stock faces substantial fundamental risks from negative profitability and cash burn. Investment opportunity exists if clinical developments succeed, but shareholders should weigh high operational losses against potential biotech breakthroughs in the neuroplastogenic therapeutics space.

Returns comparison

Trailing returns across standard periods

About Trump Media and Technology Group Corp

Trump Media & Technology Group is a media firm rooted in social media and digital streaming. Its flagship product, Truth Social, provides a platform focused on free speech and open conversation.

Read more on DJT

About Enveric Biosciences Inc

Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.

Read more on ENVB